Clonazepam
| Evidence Level: L3 | Predicted Indications: 3 |
Table of Contents
- Clonazepam
- Pharmacist Assessment Report
- Clonazepam: Benzodiazepine (GABA-A positive allosteric modulator) → restless legs syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Clonazepam: Benzodiazepine (GABA-A positive allosteric modulator) → restless legs syndrome
One-Sentence Summary
Clonazepam is a benzodiazepine that enhances GABA-A receptor signaling and is marketed in India in many single-ingredient and combination-containing products. The TxGNN model predicts it may be effective for restless legs syndrome, with a score of 0.9965. No clinical trials are registered in the data compiled for this report, but 20 publications (including a Cochrane systematic review, an AASM guideline, and a small placebo-controlled crossover trial) discuss this use.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | restless legs syndrome |
| TxGNN Prediction Score | 0.9965 |
| Evidence Level | L3 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on the known pharmacology of the benzodiazepine class, clonazepam enhances GABA-A receptor signaling. This may dampen sensory-motor arousal and sleep fragmentation, which are central problems in restless legs syndrome (RLS) and periodic limb movements during sleep.
Clinical use of clonazepam for RLS has a long history. A 1984 randomized double-blind crossover study in 6 patients reported improved subjective sleep quality and leg dysaesthesia versus placebo. A later placebo-controlled sleep-laboratory study (2001) examined acute effects of 1 mg clonazepam in RLS and periodic limb movement disorder. A 2017 Cochrane review and a 2024 historical overview have looked at benzodiazepines, including clonazepam, in RLS.
The current picture is more cautious. The 2025 American Academy of Sleep Medicine guideline positions benzodiazepines as lower-priority options than iron and alpha-2-delta ligands. Dopamine agonists are discouraged for routine use because of augmentation. Clonazepam is therefore best viewed as a second-line or selected-patient option rather than a first choice.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39324694 | 2025 | Guideline | J Clin Sleep Med | AASM clinical practice guideline for treating RLS and periodic limb movement disorder in adults and children |
| 28319266 | 2017 | Systematic Review | Cochrane Database Syst Rev | Reviews benzodiazepines, particularly clonazepam, for RLS |
| 38708125 | 2024 | Review | Tremor Other Hyperkinet Mov | Historical overview of benzodiazepines including clonazepam in RLS and periodic limb movements in sleep; about 25% of treated RLS patients in a large survey received benzodiazepines |
| 18925578 | 2008 | Review | Mov Disord | Evidence-based review of RLS treatments by a Movement Disorder Society task force |
| 36692194 | 2023 | Systematic review / meta-analysis | J Clin Sleep Med | Drug responsiveness of periodic limb movements in RLS |
| 6380197 | 1984 | Clinical study (randomized crossover) | Acta Neurol Scand | In 6 RLS patients, clonazepam significantly improved sleep quality and leg dysaesthesia versus placebo; long-term efficacy needs confirmation |
| 11313161 | 2001 | Placebo-controlled sleep-lab study | Eur Neuropsychopharmacol | Acute effects of 1 mg clonazepam on sleep and awakening quality in RLS and PLMD |
| 39787099 | 2025 | Clinical study | Sleep | Compares dopamine agonists and clonazepam on large muscle group movements in RLS |
| 20156514 | 2010 | Clinical study | Prog Neuropsychopharmacol Biol Psychiatry | Proposed dose equivalence between clonazepam and pramipexole in RLS |
| 24363103 | 2014 | Review | Neurotherapeutics | Overview of RLS treatment options |
India Market Information
Clonazepam is marketed in India. The data compiled for this report show at least 20 valid single-ingredient records, none cancelled; the list may be partial. The records carry no approved-indication text. Main entries:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 41018 | Clone 0.5mg Tablet MD | Strip of 10 tablet MD | Not recorded |
| 51272 | Cnzep 1mg Tablet | Strip of 10 tablets | Not recorded |
| 43753 | Clonatrix 1mg Tablet | Strip of 10 tablets | Not recorded |
| 35586 | Clozepam 0.5mg Tablet MD | Strip of 10 tablet MD | Not recorded |
| 36076 | Clonorest 0.25mg Tablet | Strip of 10 tablets | Not recorded |
Safety Considerations
- Drug Interactions: 278 interactions were identified in total. Major-level interactions include morphine and liposomal morphine (additive central nervous system and respiratory depression is the usual concern with opioids). Moderate-level examples include bupropion, aprepitant, omeprazole, cimetidine, clarithromycin, dronabinol, metoclopramide, nabilone, opium and sibutramine.
- Conditions of concern: Listed as contraindicated or problematic for this drug are liver failure and liver disease, kidney disease, porphyria, gallbladder disease, open-angle and angle-closure glaucoma, sleep apnea syndromes, respiratory failure, and substance-related disorders or dependence.
- Other considerations from the literature: Long half-life raises concerns about next-day sedation, accumulation and dependence with long-term use. A case report links clonazepam to mania (1991).
Please also refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Decades of clinical experience, a Cochrane review, small placebo-controlled studies and current guideline discussion support clonazepam as a possible option for restless legs syndrome. However, no registered clinical trials exist, the controlled data are small and old, and the 2025 guideline ranks benzodiazepines below other options. Dependence, sedation and respiratory risks require careful patient selection.
To proceed, the following is needed:
- Larger, modern randomized controlled trials against current first-line treatments (iron, alpha-2-delta ligands)
- Detailed mechanism of action data
- Package insert warnings and contraindications for the Indian products
- A risk plan covering sleep apnea, respiratory disease, liver and kidney impairment, opioid co-use and dependence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.